Research programme: anticancer therapeutics - Beijing Tri-Prime Genetic Engineering
Latest Information Update: 05 Sep 2007
At a glance
- Originator Beijing Tri-Prime Genetic Engineering
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jul 2004 Preclinical trials in Cancer in China (unspecified route)